Consistent with this concept, we found that pre-treatment of AML cells with AZA resulted in higher absolute numbers of CD4+ CTLA-4negative CAR T cells compared to the CAR T cell only treated group. This evidence concerns the gene CD4 and acute myeloid leukemia.